|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2008 / August 2008 / August 16, 2008 Personalized immunotherapy to combat HIV/AIDS developed |
Structure of key breast cancer target enzyme unraveled
A researcher at Hauptman-Woodward Medical Research Institute has moved a step closer to a cure, and possibly the prevention, of the most common type of breast cancer. ANI
Smoking claimed 673,000 Chinese lives in 2005
A multinational research team, led by scientists at Tulane University School of Public Health and Tropical Medicine, has lent more force to the suggestion that smoking is a significant risk factor for mortality and disease. ANI
Genetic mutations can predict childhood leukaemia relapse
A collaborative study by American researchers has revealed that changes in a gene called IKAROS can help predict a high likelihood of relapse in children with acute lymphoblastic leukaemia (ALL). ANI
A research team from Research Institute of the McGill University Health Centre (MUHC), along with researchers from Universite de Montreal have developed a personalized immunotherapy to fight HIV/AIDS.
Washington, Aug 16 : A research team from Research Institute of the McGill University Health Centre (MUHC), along with researchers from Universite de Montreal have developed a personalized immunotherapy to fight HIV/AIDS.
Scientists have long been finding it difficult to create an AIDS vaccine due to high genetic variability of the HIV virus.
"Our approach is unique in the world: no one else has yet developed customized immunotherapy using the virus from individual patients," said . Dr. Jean-Pierre Routy, from MUHC.
"This experimental technique remains long and costly for the moment, but we're hoping it will hold the promise of a completely innovative and widely available treatment in the future," he added
This immunotherapy is based on the properties of dendritic cells, whose role is to present specific proteins from infectious organisms at their surface, thereby alerting the rest of the immune system.
In collaboration with Argos Therapeutics, the researchers designed a study in which the dendritic cells of nine study patients were multiplied in vitro and then treated with the RNA (ribonucleic acid) from the virus that had infected each patient. A virus sample was taken before the administration of any antiretroviral treatment.
The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes.
After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity.
"At this stage, we have shown that the technique doesn't cause side effects or an undesirable auto-immune response," said Dr. Routy.
ANI
